Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01566877 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers
A Phase 1 study of Marburg Hemorrhagic Fever, sponsored by Sarepta Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT01566877 is a Phase 1 study of Marburg Hemorrhagic Fever that has completed, run by Sarepta Therapeutics. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01566877, a Phase 1 study of Marburg Hemorrhagic Fever, has completed, sponsored by Sarepta Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and tolerability of healthy male and female subjects with intravenous (IV) infusions of AVI 7288 compared to matched placebo in and to evaluate the pharmacokinetics (PK).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG AVI-7288
Study Locations (1)
Maryland
- SNBL Clinical Pharmacology Center, Inc. - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01566877
The ClinicalTrials.gov registry entry for NCT01566877 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarepta Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Marburg Hemorrhagic Fever appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01566877 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01566877 about?
NCT01566877 is a clinical study titled "A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers". The purpose of this study is to evaluate the safety and tolerability of healthy male and female subjects with intravenous (IV) infusions of AVI 7288 compared to matched placebo in and to evaluate the pharmacokinetics (PK).
What is the current status of trial NCT01566877?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2013-05. Estimated completion is 2014-01.
What conditions does trial NCT01566877 study?
This clinical trial studies the following conditions: Marburg Hemorrhagic Fever.
What interventions are being tested in trial NCT01566877?
The interventions under investigation include: Placebo (OTHER), AVI-7288 (DRUG).
Who is sponsoring clinical trial NCT01566877?
This trial is sponsored by Sarepta Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01566877 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.